Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2019-05-16 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Natco Pharma Limited has informed the Exchange regarding Closure of Buy Back on May 16, 2019
Regulatory Filings
2019-05-16 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Natco Pharma's marketing partner Alvogen has received FDA approval for a specific drug (Nitroglycerin Sublingual Tablets). It is addressed to stock exchanges and is intended for public information. The content is a corporate announcement about a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is short (1878 characters) and it is clearly a press release rather than a detailed report or filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for general regulatory announcements and corporate news that do not fit other specific categories.
2019-05-08 English
Natco's marketing partner Alvogen receives FDA approval for Nitroglycerin Sublingual Tablets
Regulatory Filings
2019-05-08 English
Extinguishment
Transaction in Own Shares Classification · 100% confidence The document is a letter addressed to stock exchanges regarding the buyback of equity shares by Natco Pharma Limited. It references the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, and details the extinguishment of shares as part of the buyback process. The content focuses on the company's share repurchase activity rather than financial results, management changes, or regulatory filings unrelated to capital structure. The document length is short (1652 characters), and it is not an announcement of a report publication but a direct communication about share buyback. Therefore, the appropriate classification is a Transaction in Own Shares (POS).
2019-05-08 English
certificate under regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the period ended 31st March, 2019
Regulatory Filings
2019-05-06 English
Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (64 characters) and contains no substantive content, financial data, or any indication of report type. It only includes a placeholder for an omitted picture and no other information. Given the lack of content, this cannot be classified as a full report or detailed filing. It is best classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous or insufficient filings.
2019-05-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.